Status:
NOT_YET_RECRUITING
Acute Effect of Capsimax on Resistance Exercise Performance, Muscle Oxygenation, Nitric Oxide Release, Resting Energy Expenditure and Reaction Time
Lead Sponsor:
Hofstra University
Collaborating Sponsors:
OmniActive Health Technologies
Conditions:
None Volunteer
Eligibility:
MALE
18-35 years
Phase:
NA
Brief Summary
Capsimax is a novel, proprietary encapsulated form of capsaicin, a natural and bioactive phytochemical found in chili pepper and other spicy food. The purpose of this study is to investigate the effec...
Detailed Description
Capsimax is a novel, proprietary encapsulated form of capsaicin, a natural and bioactive phytochemical found in chili pepper and other spicy food. The purpose of this study is to investigate the effec...
Eligibility Criteria
Inclusion
- Male subjects aged between 18-35 years (both limits inclusive).
- Subjects must have a BMI of 18.5 to 29.9 kg/m2 (both limits inclusive)
- Subjects must have greater than one year of resistance training experience at a frequency of 2 days per week.
- Subjects must be proficient in the barbell back squat exercise.
- Subjects must be free of any physical limitations or chronic illness that may affect performance.
- Subjects must be free of any medications.
- Subjects who agree to refrain from consuming alcohol 24 hours prior to the visit days.
- Subjects who agreed to refrain from consuming caffeine and caffeine-containing products 12 hour prior to visit days
- Subject willing to provide written consent.
Exclusion
- Subjects who have hypersensitivity or history of allergy to the study product.
- Subjects with inability to swallow soft gel capsules.
- Subjects with any other medical condition that might adversely impact the safety of the study participants or confound the study results.
- Subjects who require medications.
- Subjects who regularly use a dietary supplement containing Capsimax or other ingredients that would impact study endpoints.
- Subjects who had been treated with any investigational drug or investigational device within a period of 3 months prior to study entry
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06612658
Start Date
October 1 2024
End Date
May 30 2025
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hofstra University
Hempstead, New York, United States, 11549